Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 December 2024
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 November 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Lung cancer: diagnosis and management (NG122)Product type:GuidanceProgramme:NICE guidelineLast updated: 8 March 2024Published: 28 March 2019
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12)Product type:GuidanceProgramme:Health technology evaluationPublished: 28 September 2023
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2023
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2023
AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)Product type:GuidanceProgramme:Diagnostics guidancePublished: 5 July 2023
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 June 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) (TA884)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 March 2023
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2022
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 August 2022
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2022
Thopaz+ portable digital system for managing chest drains (MTG37)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 6 June 2022Published: 21 March 2018
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 May 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 March 2022
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)Product type:GuidanceProgramme:Diagnostics guidancePublished: 23 February 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 February 2022
Microwave ablation for primary or metastatic cancer in the lung (IPG716)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 2 February 2022
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 January 2022
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 January 2022
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 September 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 July 2021
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 June 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 March 2021
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2021
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2020
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 October 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 October 2020
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 October 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 August 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 May 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 May 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 January 2020
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 August 2019
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2019
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 July 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 May 2018
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2018
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 11 January 2017
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 10 August 2017Published: 23 June 2010
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 May 2017
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 March 2017
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 March 2017
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2016
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2015
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2015
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 April 2014
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)Product type:GuidanceProgramme:Diagnostics guidancePublished: 14 August 2013
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 February 2013
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 October 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2012
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2011
Percutaneous radiofrequency ablation for primary or secondary lung cancers (IPG372)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 15 December 2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2010
Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions (IPG337)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 March 2010
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2009
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 September 2009
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2008
Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses (IPG254)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 February 2008
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2007
Living-donor lung transplantation for end-stage lung disease (IPG170)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 May 2006
Cryotherapy for malignant endobronchial obstruction (IPG142)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2005
Photodynamic therapy for localised inoperable endobronchial cancer (IPG137)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2005
Photodynamic therapy for advanced bronchial carcinoma (IPG87)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 August 2004
Stent placement for vena caval obstruction (IPG79)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 July 2004
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 October 2022
Artificial intelligence for analysing chest CT images (MIB243)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 January 2021
Archimedes for biopsy of suspected lung cancer (MIB211)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 June 2020
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 October 2019
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)Product type:AdviceProgramme:Medtech innovation briefingPublished: 18 January 2018
HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)Product type:AdviceProgramme:Medtech innovation briefingPublished: 7 November 2017
ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)Product type:AdviceProgramme:Medtech innovation briefingPublished: 30 September 2015
Lung cancer in adults (QS17)Product type:Quality standardLast updated: 13 December 2019Published: 26 March 2012
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016